~~<i id='BFFD7CAC62'><strike id='BFFD7CAC62'><tt id='BFFD7CAC62'><pre id='BFFD7CAC62'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

fashion

author：comprehensive 2025-10-02 23:47:54 - browse：4221

Sarepta Therapeutics said Monday afternoon that its gene therapy for Duchenne muscular dystrophy failed to improve muscle function compared to a placebo in a large clinical trial — likely a major disappointment for patients and doctors who have been desperately awaiting the treatment for years.

The company said all patients in the study improved and that secondary measurements indicated the drug was having an effect. Nevertheless, the results are likely to raise questions about whether the Food and Drug Administration will expand access to the medicine.

Trading in Sarepta shares was halted at $107 with the release of the study results.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Sarepta Duchenne therapy fails to meet primary endpoint in trial

leisure time

explore

hotspot

explore

Wikipedia

RYANM.KELLY/AFPviaGettyImagesOurmindshaveaweirdandwondrouswayoftransportingustootherplacesandtimes.Y

WSS

Explaining an after

General Catalyst, Summa Health deal will turn on physician buy

Congressmen charge Covid hearing ‘could have been an email’

Biden administration opens offers in Medicare drug price negotiations

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

All of Us, NIH's precision medicine initiative, gets a big boost

focus

fashion

leisure time

At least 13 dead in Texas as scorching temps continue

Travis Kelce and the trap of celebrity vaccine endorsements

Tori Bowie and the unacceptable rates of Black maternal death

How neuroscience research could help beat back brain cancer

Bright Health sells Medicare Advantage business to Molina

All of Us, NIH's precision medicine initiative, gets a big boost

Wildfire smoke exposes gaps in outdoor worker protections

Some dementia cases could be undiagnosed liver disease

How to save PrEP access — and even expand it

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

explore

Juul spent big to court Black leaders to promote its e

Coloradans with cystic fibrosis could lose access to Trikafta

Lung cancer screening guidelines updated for cigarette smokers

The lessons of Aduhelm, an Alzheimer's drug that was not to be

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Brain injuries and the importance of a second opinion

explore

hotspot

explore

Wikipedia